A novel selective URAT1 inhibitor, AR882, further reduces serum uric acid levels and tophi compared with allopurinol in patients with gout, investigators reported in a late-breaking abstract at ...

The Food and Drug Administration (FDA) has granted Fast Track designation to AR882 for the treatment of clinically visible tophi in patients with gout.

In untreated gout, development of subcutaneous tophi is typically a late feature of disease, occurring more than 10 years after development of gout flares. [2, 3] Tophi are more frequently ...

Bone erosion in patients with gout and tophi was associated with tophi duration, drinking history, ulceration, and serum creatinine levels.

AR882 is a novel and selective URAT1 inhibitor currently in clinical stage development for the treatment of gout with tophi.